DexCom Target of Unusually Large Options Trading (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the recipient of unusually large options trading activity on Thursday. Traders acquired 10,495 call options on the company. This represents an increase of 87% compared to the typical daily volume of 5,616 call options.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock worth $25,530,859 in the last three months. Insiders own 0.41% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. DSM Capital Partners LLC acquired a new position in DexCom during the 4th quarter valued at approximately $28,000. Riverview Trust Co acquired a new position in DexCom during the 1st quarter valued at approximately $32,000. Valley National Advisers Inc. increased its stake in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. increased its stake in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co increased its stake in DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.0 %

Shares of NASDAQ DXCM traded down $1.33 during trading hours on Thursday, hitting $136.54. 1,407,097 shares of the stock were exchanged, compared to its average volume of 2,941,685. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The company has a market cap of $54.07 billion, a PE ratio of 105.25, a PEG ratio of 2.30 and a beta of 1.20. The firm has a fifty day moving average price of $130.58 and a 200-day moving average price of $117.88. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 EPS. On average, sell-side analysts expect that DexCom will post 1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James boosted their price objective on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.